uncontrolled evidence
play

Uncontrolled evidence in rare cancers Paolo G. Casali - PowerPoint PPT Presentation

Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it R Eur Eur J C J Can ance cer 201 r 2011;47 1;47:249 :2493 Clinical decision-making Methods to combine evidence New study designs


  1. Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it

  2. R

  3. Eur Eur J C J Can ance cer 201 r 2011;47 1;47:249 :2493

  4. Clinical decision-making  Methods to combine evidence  New study designs  Surrogate end points  Organization of studies 

  5. Prospective clinical data bases

  6. «Big clinical data»…

  7. Phase I  MTD dose! activity! Phase II Phase III  OR  OS efficacy!  QoL standard

  8. Lung cancer Boolell V et al. Cancers 2015;71815

  9. Soft tissue sarcomas & GIST …….

  10. STS: advanced disease ADM 75 mg/sqm R ADM 75 mg/sqm + IFX 7.5 g/sqm EORTC Soft Tissue & Bone Sarcoma Group

  11. La Lanc ncet et On Onco col l 20 2014 14;15:41 ;15:415

  12. J Clin Oncol 2015;Epub

  13. Mol Cancer Therap 2009;8:449

  14. Van an Der er Gra Graaf af WTA WTA et et al, al, La Lanc ncet et 20 2012 12;379 ;379:187 :1879

  15. Van an Der er Gra Graaf af WTA WTA et et al, al, La Lanc ncet et 20 2012 12;379 ;379:187 :1879

  16. Italiano A et al. Patterns of care and outcome of patients (pts) with metastatic soft-tissue sarcoma (STS) according to histological subtype and treatment setting: The METASTAR study. ASCO Ann. Meet. 2016, #11014

  17. Leiomyosarcoma ADM GEM TRB DTIC PAZO

  18. t T response progression

  19. Tumor response as a surrogate

  20. Quality of life -% ?

  21. Quality of life -% ?

  22. Survival… -% ?

  23. BMJ 2003;327:1459

  24. N N Eng Engl l J M J Med ed 198 1987;31 7;316:25 6:250

  25. GIST: tumor response

  26. GIST: tumor response Choi’s 10% 15%

  27. Choi’s RECIST

  28. -13 HU 9 HU 15 HU 36 HU 83 HU - 18 HU -34 HU -9 HU 5 HU 9 HU 52 HU 57 HU - 2 HU 61 HU 3 HU 13 HU 5 HU 20 HU 39 HU 3 HU 10 HU 57 HU

  29. Immune therapies: tumor response Postow MA et al. J Clin Oncol 2015;33:1974

  30. Karnofsky DA, 1961;6:709

  31. Reliability (reproducibility) = !

  32. J Na J Natl tl Can ance cer r In Inst 2 st 200 000;92 0;92:205 :205

  33. J Na J Natl tl Can ance cer r In Inst 2 st 200 000;92 0;92:205 :205

  34. 1. Personalized tool -% ?

  35. 2. Volume

  36. 3. Non-dimensional changes

  37. 4. Temporal dimension t

  38. 5. Continuous variable

  39. 6. Growth rate t

  40. t

  41. Boo ooth th CM et et al. al. Eur J C Eur J Can ance cer r 20 2008 08;44:25 ;44:25

  42. Con ontr troll oll Cli lin n Trials rials 20 2000 00;21:34 ;21:343

  43. Reliability (reproducibility) = !

  44. paolo.casali@istitutotumori.mi.it @casali_pg

Recommend


More recommend